SANTA BARBARA, Calif.,
Oct. 16, 2013 /PRNewswire/ -- VG Life
Sciences, Inc. (VGLS) is a publicly traded biotechnology company
focused on developing treatments for patients suffering autoimmune
and infectious diseases.
VG Life Sciences is pleased to announce the engagement of KWCO,
PC Certified Public Accountants to conduct the Company's (VGLS)
audit, oversee Securities and Exchange Commission (SEC) filings and
facilitate the Company becoming fully reporting under the
Securities Exchange Act of 1934. VG Life Sciences will become a
fully reporting Company and produce consolidated balance sheets of
the Company as of December 31, 2012
and 2013. It will also include related consolidated statements of
operations, stockholders' equity and yearly cash flows from the
Company's inception in 1995 through the end of this year.
"This is yet another step intended to build confidence and
restore financial accountability to the Company's present and
future investors and shareholders. Methodically, we will then be
taking the necessary steps for the Company to be re-listed on OTC
Bulletin Boards likely in the first quarter of 2014." Says John
Tynan, Interim President and CEO of VG Life Sciences.
The completion of this audit will improve internal controls,
improve transparency and result in more timely, detailed
information about the Company and its ownership. This audit will
also enable VG Life Sciences to file Form 10 with the SEC, a fiscal
priority for the Company as outlined in the July 18,
2013 Letter to Shareholders.
About VG Life Sciences Inc.
Santa Barbara, California-based
VG Life Sciences Inc., formerly known as Viral Genetics, is a
biotechnology company working on discovering and developing drug
therapies for infectious diseases, cancer and many autoimmune
diseases. VGLS controls over 50 US and international patents and
patents pending protecting its exclusive biotech platform
technologies. For more information and upcoming events, visit
www.vglifesciences.com or find VG Life Sciences, Inc. on Facebook,
Twitter, and LinkedIn.
Safe Harbor Statement and Forward-Looking Statements
This news release may contain forward-looking statements that
involve risks and uncertainties associated with financial
projections, milestone timelines, clinical development, regulatory
approvals and other risks described by VG Life Sciences from time
to time in its periodic reports. None of VG Life Sciences' drug
compounds are approved by the US FDA or by any comparable
regulatory agencies elsewhere in the world. Therefore, there can be
no assurance that the forward-looking statements included in this
release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included
herein, the forward-looking statements should not be regarded as a
representation by VG Life Sciences or any other person that the
objectives and plans of VG Life Sciences will be achieved.
Contact:
Alexandria Sumner, Director of
Corporate Communications
VG Life Sciences, Inc.
Phone: (805) 679-6763
Email: asumner@vglifesciences.com
SOURCE VG Life Sciences, Inc.
SOURCE VG Life Sciences, Inc.